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diagnostic criteria, additional investigation techniques and determine target therapies for each 
patient, in order to improve their clinical outcome.  
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Background. Heart failure (HF) is the final common pathway of many cardiovascular diseases. 
It imposes significant socio-economic and health care burden to both patients and healthcare 
systems. Although the most common cause of HF is ischemic heart diseases, other less 
common causes such as hyperthyroidism (thyrotoxicosis), severe anemia, arrhythmia should 
also be considered during diagnosis to improve overall clinical management of HF.   
Case report. The 42-year-old man was admitted to cardiology department with mixed 
(inspiratory and expiratory) dyspnea at moderate effort, palpitations, fatigue, the loss in weight 
of about 15 kg during 9-10 months. Anamnesis: general condition worsened the last 2 months 
when appeared generalized edema and mixed dyspnea. During this time did not address to 
doctor, any treatment has not received. Physical examination revealed swelling in the legs, 
ankles, ascites, an irregular pulse, at a rate of 130 beats/min, BP- 110/70mmHg. On ECG - 
atrial fibrillation with rate - 120-57 b/min, electric axis of heart is normal. Signs of left 
ventricular hypertrophy. The chest X-ray -pulmonary congestion, bilateral pleural effusion. 
The abdominal X-ray – fluid levels with air on the left. On TTE- thickening of the walls of the 
aorta and valve apparatus. Dilatation of all heart chambers, significant dilatation of the right 
atrium and right ventricle, and moderate dilatation of the left atrium and the left ventricle. 
Contractile function of the left ventricular myocardium is moderately reduced. Ejection 
fraction = 42%. The second degree mitral regurgitation and third-fourth -degree tricuspid 
regurgitation. Moderate pulmonary arterial hypertension (PASP= 52mmHg). Sheets of the 
pericardium are thickened. Fluid in the pleural cavity up to 11 millimeters in the region of the 
right atrium. Bilateral pleurisy - inhomogeneous fluid with floating elements on the left - about 
1,000 milliliters, to the right - about 800 milliliters. Сytological analysis of fluid from pleural 
cavity pointed to the inflammatory etiology of the effusion. On the ultrasound examination of 
the thyroid gland – fourth –degree hyperplasia, multiple diffuse changes.On the ultrasound 
examination of abdominal cavity - ascites, bilateral pleuritic, diffuse changes in the 
parenchyma of the liver. The glycemic profile -7-00: 4.7 mmol/l, 13-00: 6.3 mmol/l, 17-00: 
10.6 mmol/l, glycated hemoglobin - 5,6%. Analysis of thyroid hormones- free 
Triiodothyronine – 17,22 Pmol/l, free Thyroxine – 79,52 Pmol/l. TSH – ‹ 0, 05 uIU/ml; anti 
TPO- 144 IU/ml. Tumor marker CA 19-9 - <3.0 U/ml. During hospitalization was consulted 
by endocrinologist, surgeon. After 11 days of complex treatment with diuretics, anticoagulants, 
beta-adrenoblockers, antithyroid drugs, cardiac glycosides, corticosteroids, histamine-2-
receptor blockers - the general condition improved: dyspnea and general swelling disappeared, 
general weakness was reduced.   
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Conclusions. The incidence and prevalence of thyrotoxic heart failure (THF) provide a wide 
variation from 12% to 68% in hyperthyroid patients. Up to 90% of patients with thyrotoxicosis 
may develop Atrial Fibrillation, 47% Left Ventricle systolic dysfunction and 1% dilated THF 
and a third of these cases are reversible. Mortality in THF patients is 1.2 higher than in patients 
with hypertension, valvular heart disease or coronary artery disease, and 1.4 higher than in the 
general population. Hyperthyroidism is a potentially reversible and curable cause of THF, so 
it should be excluded in every new patient with HF, especially in young patients and in the 
absence of coronary artery disease and other structural heart diseases.  
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Introduction. Atrial fibrilation is the most common cardiac arrhythmia with the worldwide 
prevalence of more than 33.5 million people and is a subject with increased interest in clinical 
trials. The reason is the awareness of the high risk of embolic events that in 75 % are 
complicated by cerebrovascular accidents. It is estimated that the number of patients with AF 
in 2030 in Europe will be 14–17 million and the number of new cases of AF per year at 
120,000–215,000. In approximately 80% of patients, atrial fibrillation is associated with 
organic heart disease including valvular heart disease (mostly mitral valve disease), coronary 
artery disease, hypertension, hypertrophic or dilated cardiomyopathy. In 20% of cases, atrial 
fibrillation occurs in the absence of organic heart disease. Besides the danger of embolic events, 
atrial fibrillation is the most common atrial arrhythmia found in Brugada syndrome which is 
associated with malignant ventricular arrhythmias and sudden cardiac death.  
Aim of the study. The purpose of this study was to review data about characteristics and 
management of atrial fibrillation in Brugade syndrome.  
Materials and methods. The source of information was represented by articles published in 
the online databases: PubMed, HINARI, SCOPUS, EMBASE 
Results. Current evidence revealed that the prevalence of AF in patients in BrS vastly differs 
among publish studies, ranged from 6% to 39%. The only genetic mechanism of arrhythmias 
is related to the mutation of the SCN5A gene that encodes cardiac sodium channels. However, 
as this sodium channel is found not only in the ventricular tissue, but also in the atria, this could 
lead to reentrant tachyarrhythmias in the atrium. Nevertheless, management of BrS with AF 
remains a difficult task, as medication for AF, such as sodium channel blockers, confers their 
risk owing to their proarrhythmic effects in patients with BrS. In addition, other than quinidine 
and disopyramide cannot be used because they block sodium channels and cause ventricular 
arrhythmias. Recent evidence suggested that catheter ablation could be utilized as a first‐line 
therapy for paroxysmal AF in BrS patients. For the last 2 decades, ICD therapy has been 
considered as the cornerstone therapy of patients with documented ventricular 
tachyarrhythmia, but recent studies has been associated ICD therapy with a significant rate of 
